Aktis Oncology
MA - BostonPharmaceutical
Focus: Aktis Oncology is a clinical-stage targeted radiopharmaceutical company focused on developing alpha-particle therapies for oncology and neurology indications. The company operates as a pre-revenue biotech with a highly specialized focus on an emerging therapeutic modality.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Aktis Oncology
AI assessmentNot HiringNo open roles listed right now. Follow Aktis Oncology to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
actinium-225 AKY-1189
Urothelial Carcinoma Bladder[225Ac]Ac-AKY-1189
Urothelial Carcinoma BladderClinical Trials (1)
Help build intelligence for Aktis Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.